Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RACHEL1: M7824 and Radiation in Metastatic HR+/HER2- Breast Cancer
NCT03524170Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2018
- Primary completion
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bintrafusp alfa in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Recommended Phase II Dose at 6 weeks and Safety and Tolerability. Started Apr 2018; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03524170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03524170.